Neuspera secured a Medicare payment win as CMS assigned its integrated sacral neuromodulation system to the same payment level as legacy implantable devices. Neuspera treats urinary urge incontinence with a miniaturized implant powered by an external device worn for about two hours daily. The approach avoids the implanted battery and replacement surgeries of conventional devices. The parity, which raises the payment rate by 11.8% to $22,150, gives Neuspera straightforward access to the roughly $1 billion legacy SNM market.

Theranica announced that insurance coverage for Nerivio, its FDA-cleared migraine wearable, has now reached 158 million lives. It is now covered for half of the US insured population. Worn on the upper arm and controlled by a smartphone app, Nerivio uses remote electrical neuromodulation to activate the body's own pain-inhibitory pathways for both acute and preventive migraine treatment. Coverage has doubled over the past 15 months.

Spark Biomedical published a first-in-human study, showing its tAN platform can enhance platelet function. Spark's device delivers non-invasive electrical stimulation at the ear to engage neural pathways involved in clot formation. The study offers the first clinical evidence that ear-based nerve stimulation can strengthen the body's natural clotting response. The findings support Spark's drug-free approach to stopping severe bleeding, with potential applications in surgery, trauma, and military settings.

Newronika received a CE Mark for the latest release of αDBS, its adaptive deep brain stimulation system. Unlike conventional DBS, which delivers constant stimulation, an adaptive system senses brain signals continuously and adjusts stimulation to match the patient's changing state. The Milan company describes this as the first approval for an adaptive DBS system that also transmits neural data into a connected cloud platform, building a longitudinal repository that grows with each patient treated. The system remains investigational in the US.

Cognito Therapeutics presented new biomarker data from its Phase 2 study at the Alzheimer's Association International Conference. The findings show that daily use of Spectris, its non-invasive sensory stimulation headset, increased cerebrospinal fluid levels of several HDL-like lipid transport proteins in patients with amyloid-positive mild cognitive impairment. The company reads the data as a coordinated biological response. The data are exploratory but reinforce a proposed mechanism for the gamma-frequency approach. A full data readout is expected next month.

EMVision had its EMView study published in npj Digital Medicine, a Nature Portfolio journal, validating the AI models behind its RF brain scanner. The peer-reviewed results show the scanner can distinguish haemorrhagic from ischaemic stroke with high sensitivity and specificity, an invaluable distinction, as the two stroke types require opposite treatments. The publication supports the Australian company's point-of-care and prehospital programs and adds new patents to its portfolio.

Time is Brain closed an oversubscribed €3M Pre-Series A, only days after receiving CE/MDR approval for its stroke-monitoring platform BraiN20. The Barcelona spinout's device tracks a proprietary brain signal, giving clinicians continuous neurological data from the moment a stroke begins. The company frames this as Real-Time Stroke Intelligence, designed to support decisions across the full patient journey. The dual milestone clears the path for commercial rollout across Europe later this year.

Universal Brain received FDA 510(k) clearance for its UB ERP System, a platform that measures brain function using EEG and event-related potentials. The system pairs a dry-electrode headset with software that captures neural responses as patients complete cognitive and emotional tasks, producing analyzed results in under five minutes. Psychiatry traditionally relies on symptom-based evaluation, with few objective tools. Universal Brain positions its approach as a way to bring physiological measurement into treatment selection and CNS drug trials. The company is preparing a commercial launch later in 2026.

Sharper Sense was named one of four recipients of New York's Empire State Development Innovation Matching Grants, which distributed $400,000 across the cohort. The NYC company builds a non-invasive single-use patch, worn on the neck, stimulating the vagus nerve. The patch is meant to enhance sensory processing, sharpening hearing, vision, and touch. Sharper Sense is exploring high-stakes fields, including military and aviation. Founder Charles Rodenkirch told Neurofounders that its technology could eventually be used for any context where someone currently would benefit from stimulants.

CraniUS received an initial $1.1M award from the NIH Blueprint MedTech program, with the potential to increase to $4M. The Baltimore company builds NeuroPASS, a fully implantable, skull-embedded device designed to bypass the blood-brain barrier and deliver drugs directly into brain tissue. The funding supports engineering, manufacturing, and regulatory work toward a first-in-human study. The first application explored is recurrent glioblastoma, the most common malignant primary brain tumour in adults.

Zeta Surgical received FDA 510(k) clearance for its TMS Robotic System. The system robotically positions TMS coils using 3D patient imaging and tracks head movement up to 20 times per second. Zeta achieves sub-millimeter accuracy without cranial pins or anaesthesia. TMS is increasingly used for treatment-resistant depression, but many clinics still place coils freehand. Initial deployment of Zeta's robotic approach has begun at HOPE Therapeutics clinics in Florida.